Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
iBio, Inc. logo — AI-Powered Precision Antibody Therapeutics

iBio, Inc.

AI-Powered Precision Antibody Therapeutics

Founded 2008 United States San Diego, United States 50 employees Post-IPO Equity Total: $53.14M Biotechnology, Robotics

General Information

Company Name iBio, Inc.
Founded Year 2008
Location United States San Diego, United States
Employees 50
Industries Biotechnology, Robotics
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with iBio, Inc.. To contact iBio, Inc., visit ibioinc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does iBio, Inc. compare?

A PDF of iBio, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting iBio, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About iBio, Inc.

iBio, Inc. is a biotechnology startup founded in 2008, based in the United States, with a mission to develop safer and more effective immunotherapies for challenging cancers through their Discovery Platform. The company's slogan "AI-Powered Precision Antibody Therapeutics" highlights their use of artificial intelligence to guide drug discovery, making therapeutic development smarter, more precise, and faster. With a focus on hard-to-drug targets, iBio has $15.00M in Post-IPO Equity investment as of 26 March 2024 from investors including Ikarian Capital, Lynx1 Capital Management, and ADAR1 Capital Management. iBio's approach addresses the essential challenge in developing antibody drugs, which traditionally involves a high degree of randomness and time-consuming, costly methods. The company's nine immuno-oncology candidates in the pipeline aim to target solid tumors, glioblastoma, and head and neck cancers. By utilizing their Discovery Platform, iBio is poised to revolutionize the precision and efficiency of therapeutic development. This approach is expected to yield a higher success rate in bringing potentially life-saving drugs to market, thereby challenging the status quo in drug discovery and development.

Business keywords: AI-powered drug discovery, Precision medicine, Immunotherapy, Antibody therapeutics, Biopharmaceuticals, Cancer treatment, Artificial intelligence in drug development, Monoclonal antibodies, Biologics production, Green plant transient gene expression, Bioprocessing technology, Drug target identification, Immuno-oncology, Biosimilar products, Pandemic disease response

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $15.00M 3
Ikarian Capital
Ikarian Capital, Lynx1 Capital Management +1
26 Mar 2024
Post IPO Equity $3.50M -
06 Dec 2022
Post IPO Debt $22.38M 1
Woodforest National Bank
01 Nov 2021
Post IPO Equity $2.20M -
10 Feb 2016
Post IPO Equity $7.07M -
13 Nov 2010
Post IPO Equity $3.00M -
22 Sep 2009

FAQ About iBio, Inc.

AI-Powered Precision Antibody Therapeutics
iBio, Inc. was founded in 2008.
iBio, Inc. is headquartered in San Diego, United States.
iBio, Inc. operates in Biotechnology and Robotics. Its work centres on AI-powered drug discovery, Precision medicine, Immunotherapy and Antibody therapeutics.
iBio, Inc. has approximately 50 employees.
iBio, Inc. has completed 6 funding rounds, raising a total of $53.14M. The latest funding stage is Post-IPO Equity.

We're actively collecting intelligence on iBio, Inc..

Source: BounceWatch company record for iBio, Inc., https://bouncewatch.com/company/ibio-inc, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout